Outcomes after allogeneic haematopoietic stem cell transplantation in young adults in Germany
Standard
Outcomes after allogeneic haematopoietic stem cell transplantation in young adults in Germany. / Frietsch, Jochen J; Flossdorf, Sarah; Beck, James F; Kröger, Nicolaus; Fleischhauer, Katharina; Dreger, Peter; Schetelig, Johannes; Bornhäuser, Martin; Hochhaus, Andreas; Hilgendorf, Inken.
In: BRIT J HAEMATOL, Vol. 201, No. 2, 04.2023, p. 308-318.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Outcomes after allogeneic haematopoietic stem cell transplantation in young adults in Germany
AU - Frietsch, Jochen J
AU - Flossdorf, Sarah
AU - Beck, James F
AU - Kröger, Nicolaus
AU - Fleischhauer, Katharina
AU - Dreger, Peter
AU - Schetelig, Johannes
AU - Bornhäuser, Martin
AU - Hochhaus, Andreas
AU - Hilgendorf, Inken
N1 - © 2022 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
PY - 2023/4
Y1 - 2023/4
N2 - Young adults (YA) represent a minority among recipients of allogeneic haematopoietic stem cell transplantation (HSCT). In order to describe the outcome of YA following HSCT in Germany, 9299 patients who were registered with the German Registry for Stem Cell Transplantation were included in this retrospective analysis of the years 1998-2019. The impact of the variables, such as patient age and sex, sex differences, stem cell source, donor type, conditioning, year of HSCT, the diagnosis, and the achieved remission status were tested in univariable and multivariable analysis for overall, event-free and relapse-free survival as well as for the cumulative incidences of non-relapse and therapy-related mortality. Altogether, the outcome of YA after HSCT improved over time and was determined by the underlying disease, the age at disease onset, stem cell source, and donor type. Patients were most likely to die from relapse, and survival of HSCT recipients after 10 years was reduced by more than half in comparison to the general population of YA. Deeper understanding of modifiable risk factors may be gained by studies comparing the outcome of YA post-HSCT with that of children, adolescents and elderly patients. A deliberate and strong patient selection may further improve mortality rates.
AB - Young adults (YA) represent a minority among recipients of allogeneic haematopoietic stem cell transplantation (HSCT). In order to describe the outcome of YA following HSCT in Germany, 9299 patients who were registered with the German Registry for Stem Cell Transplantation were included in this retrospective analysis of the years 1998-2019. The impact of the variables, such as patient age and sex, sex differences, stem cell source, donor type, conditioning, year of HSCT, the diagnosis, and the achieved remission status were tested in univariable and multivariable analysis for overall, event-free and relapse-free survival as well as for the cumulative incidences of non-relapse and therapy-related mortality. Altogether, the outcome of YA after HSCT improved over time and was determined by the underlying disease, the age at disease onset, stem cell source, and donor type. Patients were most likely to die from relapse, and survival of HSCT recipients after 10 years was reduced by more than half in comparison to the general population of YA. Deeper understanding of modifiable risk factors may be gained by studies comparing the outcome of YA post-HSCT with that of children, adolescents and elderly patients. A deliberate and strong patient selection may further improve mortality rates.
U2 - 10.1111/bjh.18610
DO - 10.1111/bjh.18610
M3 - SCORING: Journal article
C2 - 36573337
VL - 201
SP - 308
EP - 318
JO - BRIT J HAEMATOL
JF - BRIT J HAEMATOL
SN - 0007-1048
IS - 2
ER -
